Synthetic Biologics, Inc. - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 35 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Synthetic Biologics, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Synthetic Biologics, Inc. - Product Pipeline Review - 2014', provides an overview of the Synthetic Biologics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Synthetic Biologics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Synthetic Biologics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Synthetic Biologics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Synthetic Biologics, Inc.'s pipeline products

Reasons to buy

- Evaluate Synthetic Biologics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Synthetic Biologics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Synthetic Biologics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Synthetic Biologics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Synthetic Biologics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Synthetic Biologics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Synthetic Biologics, Inc. Snapshot 5
Synthetic Biologics, Inc. Overview 5
Key Information 5
Key Facts 5
Synthetic Biologics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Synthetic Biologics, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Synthetic Biologics, Inc. - Pipeline Products Glance 12
Synthetic Biologics, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Synthetic Biologics, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Synthetic Biologics, Inc. - Drug Profiles 16
estriol 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
SYN-010 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
SYN-004 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
SYN-005 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
SYN-001 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
SYN-007 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Synthetic Biologics, Inc. - Pipeline Analysis 23
Synthetic Biologics, Inc. - Pipeline Products by Target 23
Synthetic Biologics, Inc. - Pipeline Products by Route of Administration 24
Synthetic Biologics, Inc. - Pipeline Products by Molecule Type 25
Synthetic Biologics, Inc. - Pipeline Products by Mechanism of Action 26
Synthetic Biologics, Inc. - Recent Pipeline Updates 27
Synthetic Biologics, Inc. - Dormant Projects 31
Synthetic Biologics, Inc. - Discontinued Pipeline Products 32
Discontinued Pipeline Product Profiles 32
dnaJP-1 32
zinc acetate SR 32
Synthetic Biologics, Inc. - Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35

List of Tables
Synthetic Biologics, Inc., Key Information 5
Synthetic Biologics, Inc., Key Facts 5
Synthetic Biologics, Inc. - Pipeline by Indication, 2014 7
Synthetic Biologics, Inc. - Pipeline by Stage of Development, 2014 8
Synthetic Biologics, Inc. - Monotherapy Products in Pipeline, 2014 9
Synthetic Biologics, Inc. - Partnered Products in Pipeline, 2014 10
Synthetic Biologics, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 11
Synthetic Biologics, Inc. - Phase II, 2014 12
Synthetic Biologics, Inc. - Phase I, 2014 13
Synthetic Biologics, Inc. - Preclinical, 2014 14
Synthetic Biologics, Inc. - Discovery, 2014 15
Synthetic Biologics, Inc. - Pipeline by Target, 2014 23
Synthetic Biologics, Inc. - Pipeline by Route of Administration, 2014 24
Synthetic Biologics, Inc. - Pipeline by Molecule Type, 2014 25
Synthetic Biologics, Inc. - Pipeline Products by Mechanism of Action, 2014 26
Synthetic Biologics, Inc. - Recent Pipeline Updates, 2014 27
Synthetic Biologics, Inc. - Dormant Developmental Projects,2014 31
Synthetic Biologics, Inc. - Discontinued Pipeline Products, 2014 32
Synthetic Biologics, Inc., Subsidiaries 33